Based on previous large-scale in silico screening several factor Xa inhibitors were proposed
to potentially inhibit SARS-CoV-2 Mpro. In addition to their known anticoagulants activity this …

Background: Severe progression of coronavirus disease 2019 (COVID-19) causes
respiratory failure and critical illness. Recently, COVID-19 has been associated with …

Background Venous thromboembolism (VTE) frequently occurs in hospitalized patients with
coronavirus disease 2019 (COVID‐19). The optimal dose of anticoagulation for …

Objetivo: Analisar as características das coagulopatias associadas à infecção pelo novo
coronavírus. Revisão bibliográfica: Com o avanço da doença percebeu-se que além de …

COVID-19 is a fast-spreading pandemic that is caused by SARS-CoV-2 viral pathogen.
Combination therapy of the antiviral favipiravir and the anticoagulant apixaban is one of the …

Background. Most evidence regarding anticoagulation and COVID‐19 refers to the
hospitalization setting, but the role of oral anticoagulation (OAC) before hospital admission …

Background With the dire economic situation in Lebanon, many of the basic resources of the
hospitals needed to help fight COVID-19 infections are not available. In this paper, we …

Purpose: Heparin-based regimens are recommended for anticoagulation in hospitalized
patients with COVID-19 though a study reported similar mortality with apixaban in critically ill …

We describe a retrospective cohort, 156 patients with chronic lymphocytic leukemia (CLL)
diagnosed with COVID-19, analyze factors associated with a severe disease course and the …

Background: Increased rates of thromboembolism (TE) have been reported in patients with
COVID-19, even without prior predisposition to thrombosis. Cancer patients are already …